Skip to content
Subscriber Only

Glaxo, Vir Halt Enrollment in Study of Covid Antibody Treatment

Inside GSK’s Research And Development Center
Photographer: Simon Dawson/Bloomberg

GlaxoSmithKline Plc and Vir Biotechnology Inc. halted enrollment in a late-stage study of a Covid-19 antibody therapy on the recommendation of an independent monitoring board.

The study is looking at the effects of VIR-7831 in hospitalized patients, and the action was taken after “sensitivity analyses of the available data raised concerns about the magnitude of potential benefit,” according to a statement from the companies. The independent Data and Safety Monitoring Board “recommended that the VIR-7831 arm of the trial be closed to enrollment while the data mature.”